Skip to content
Peptigraph home

Cagrilintide Phase 1 trial (NCT05804162)

A Thorough QTc Study Evaluating the Effect of Cagrilintide on Cardiac Repolarisation in Healthy Participants

Registry record checked

At a glance

Phase
Phase 1
Status
Completed
Enrolment
107
actual
Start
12 Apr 2023 (actual)
Primary completion
12 Aug 2023 (actual)
Sponsor
Novo Nordisk A/S
Design

Arms and doses

NCT05804162 study arms
ArmTypeInterventionsDescription
Cagrilintide (Arm 1)ExperimentalDrug: Cagrilintide; Drug: Moxifloxacin PlaceboParticipants will receive 0.6 milligrams (mg) of cagrilintide subcutaneously once weekly and the dose will be then escalated once in 2 weeks for 8 weeks until the target maintenance dose of 4.5 mg is reached followed by a 38-day post-treatment period. In addition, a single dose of moxifloxacin placebo prior to initiation of treatment and a single dose moxifloxacin placebo at the end of the treatment period will be administered orally.
Cagrilintide Placebo (Arm 2A)Active comparatorDrug: Cagrilintide Placebo; Drug: Moxifloxacin; Drug: Moxifloxacin PlaceboParticipants will receive cagrilintide placebo subcutaenously once weekly. In addition, a single dose of moxifloxacin active prior to initiation of treatment and a single dose of moxifloxacin placebo at the end of the treatment period will be administered orally.
Cagrilintide Placebo (Arm 2B)Active comparatorDrug: Cagrilintide Placebo; Drug: Moxifloxacin; Drug: Moxifloxacin PlaceboParticipants will receive cagrilintide placebo subcutaneously once weekly. In addition, a single dose of moxifloxacin placebo prior to initiation of treatment and a single dose of moxifloxacin active at the end of the treatment period will be administered orally.
Endpoints

Primary endpoint

NCT05804162 primary outcomes
MeasureTime frame
Change From Baseline in Fridericia Heart Rate Corrected QT Interval (QTcF) At 12, 24, 48 and 72 Hours Post-Second Dose of Cagrilintide/Cagrilintide Placebo at the 4.5 mg Dose LevelFrom pre-last dose on Day 52 to 12, 24, 48 and 72 hours post-last dose on Day 55
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05804162 secondary outcomes
MeasureTime frame
Change From Baseline in Fridericia Heart Rate Corrected QT Interval (QTcF) at 2, 3 and 4 Hours Post-Dose of Moxifloxacin/Moxifloxacin PlaceboPre-dose to 2, 3 and 4 hours post-dose on Day 2 and Day 55
Change from Baseline in QT Interval Corrected Individually for HR (QTcI) at 12, 24, 48 and 72 Hours Post-Second Dose of Cagrilintide/Cagrilintide Placebo at the 4.5 mg Dose LevelFrom pre-last dose on Day 52 to 12, 24, 48 and 72 hours post-last dose on Day 55
Occurrence of Absolute QTcF Interval Prolongation: QTcF Interval > 450 millisecond (ms), QTcF Interval > 480 ms and QTcF Interval > 500 msB on ECG Recordings 0-72 Hours after Cagrilintide/Cagrilintide Placebo at the 4.5 mg Dose LevelsFrom pre-last dose on Day 52 to 72 hours post-last dose on Day 55
Occurrence of QTcF Interval Increases from Baseline > 30 ms and QTcF Interval Increases from Baseline > 60 ms Based on ECG Recordings 0-72 Hours after Cagrilintide/Cagrilintide Placebo at the 4.5 mg Dose LevelsFrom pre-last dose on Day 52 to 72 hours post-last dose on Day 55
Change from Baseline in QT Interval Corrected Individually for HR (QTcI) at 2, 3 and 4 Hours Post-Dose of Moxifloxacin/Moxifloxacin PlaceboPre-dose to 2, 3 and 4 hours post-dose on Day 2 and Day 55
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
55 Years
Results

Results

No results posted on ClinicalTrials.gov as of 11 Oct 2026.

Cardiac repolarisation check on cagrilintide 4.5 mg

Healthy volunteers were randomised to cagrilintide escalated to 4.5 mg weekly or to placebo, and the primary endpoint tracked QTcF change at 12, 24, 48 and 72 h after the last 4.5 mg dose.[2]

Safety was judged against a 10 ms ceiling on the upper limit of the two-sided 90% confidence interval at each of the four time points.[2]

Of 105 participants (53 on cagrilintide, 52 on placebo), none showed clinically relevant QTcF prolongation, with every upper limit below 10 ms.[2]

Moxifloxacin 400 mg served as the positive control in the placebo arms to establish assay sensitivity.[2]

Sources

  1. 1A Thorough QTc Study Evaluating the Effect of Cagrilintide on Cardiac Repolarisation in Healthy ParticipantsClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 11 Oct 2026
  2. 2Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.Diabetes, obesity & metabolism · 2024PMID 39279639Accessed 2 Oct 2026

Found an error? Report a correction.